Provided are uses of an anti-PD-1 antibody and an anti-LAG-3 antibody jointly in preparing a medicament for treating tumor. Specifically, related are uses of the anti-PD-1 antibody or an antigen-binding fragment thereof and the anti-LAG-3 antibody or an antigen-binding fragment thereof jointly in preparing a medicament for treating tumor and/or enhancing T cell activities.